Luhua Group

Luhua Group, specifically referring to the Shandong Lu Hua Investment Holding Group (now a core component of the state-owned Shandong Health Group), is a prominent Chinese conglomerate with a strong focus on the pharmaceutical and healthcare sectors. Its key subsidiary, Shandong Lu Hua Pharmaceutical, is a major global supplier of animal-derived biochemical APIs and finished dosages, specializing in heparin-based products. The company's portfolio includes Heparin Sodium, Enoxaparin Sodium, Chondroitin Sulfate, and various digestive enzymes such as Pancreatin and Pepsin. With integrated manufacturing capabilities from raw material collection to final product formulation, Luhua Group serves both domestic and international markets under strict GMP standards. Following its integration into Shandong Health Group in 2020, the company continues to play a vital role in the regional Big Health industry initiative.